Amnion derived adherent cells

Abstract

Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.

1 .- 38 . (canceled) 
     
     
         39 . A method of treating an individual having a disease or disorder of the circulatory system, comprising administering to said individual a population of cells, wherein at least 50% of the cells in said population are human amnion-derived adherent cells, wherein said amnion derived adherent cells are adherent to tissue culture plastic, and wherein said amnion derived adherent cells are OCT-4 −  as determinable by RT-PCR, and CD49f + , CD90 + , and HLA-G −  as determinable by flow cytometry. 
     
     
         40 . The method of  claim 39 , wherein at least 70% of the cells in said population are said amnion derived adherent cells. 
     
     
         41 . The method of  claim 39 , wherein at least 80% of the cells in said population are said amnion derived adherent cells. 
     
     
         42 . The method of  claim 39 , wherein at least 90% of the cells in said population are said amnion derived adherent cells. 
     
     
         43 . The method of  claim 39 , wherein at least 95% of the cells in said population are said amnion derived adherent cells. 
     
     
         44 . The method of  claim 39 , wherein at least 99% of the cells in said population are said amnion derived adherent cells. 
     
     
         45 . The method of  claim 39 , wherein said population of cells is formulated in a hydrogel solution. 
     
     
         46 . The method of  claim 39 , wherein said disease or disorder of the circulatory system is myocardial infarction. 
     
     
         47 . The method of  claim 39 , wherein said disease or disorder of the circulatory system is cardiomyopathy. 
     
     
         48 . The method of  claim 39 , wherein said disease or disorder of the circulatory system is aneurysm, angina, aortic stenosis, aortitis, arrhythmias, arteriosclerosis, arteritis, asymmetric septal hypertrophy (ASH), atherosclerosis, atrial fibrillation and flutter, bacterial endocarditis, Barlow's Syndrome (mitral valve prolapse), bradycardia, Buerger's Disease (thromboangiitis obliterans), cardiomegaly, carditis, carotid artery disease, coarctation of the aorta, congenital heart defects, congestive heart failure, coronary artery disease, Eisenmenger's Syndrome, embolism, endocarditis, erythromelalgia, fibrillation, fibromuscular dysplasia, heart block, heart murmur, hypertension, hypotension, idiopathic infantile arterial calcification, Kawasaki Disease (mucocutaneous lymph node syndrome, mucocutaneous lymph node disease, infantile polyarteritis), metabolic syndrome, microvascular angina, myocarditis, paroxysmal atrial tachycardia (PAT), periarteritis nodosa (polyarteritis, polyarteritis nodosa), pericarditis, peripheral vascular disease, critical limb ischemia, phlebitis, pulmonary valve stenosis (pulmonic stenosis), Raynaud's Disease, renal artery stenosis, renovascular hypertension, rheumatic heart disease, diabetic vasculopathy, septal defects, silent ischemia, syndrome X, tachycardia, Takayasu's Arteritis, Tetralogy of Fallot, transposition of the great vessels, tricuspid atresia, truncus arteriosus, valvular heart disease, varicose ulcers, varicose veins, vasculitis, ventricular septal defect, Wolff-Parkinson-White Syndrome, endocardial cushion defect, acute rheumatic fever, acute rheumatic pericarditis, acute rheumatic endocarditis, acute rheumatic myocarditis, chronic rheumatic heart diseases, diseases of the mitral valve, mitral stenosis, rheumatic mitral insufficiency, diseases of aortic valve, diseases of other endocardial structures, ischemic heart disease (acute and subacute), angina pectoris, acute pulmonary heart disease, pulmonary embolism, chronic pulmonary heart disease, kyphoscoliotic heart disease, myocarditis, endocarditis, endomyocardial fibrosis, endocardial fibroelastosis, atrioventricular block, cardiac dysrhythmias, myocardial degeneration, cerebrovascular disease, a disease of arteries, arterioles and capillaries, or a disease of veins and lymphatic vessels. 
     
     
         49 . The method of  claim 39 , wherein said population of cells comprising amnion-derived adherent cells further comprises a second type of cells. 
     
     
         50 . The method of  claim 49 , wherein said second type of cells are embryonic stem cells, hematopoietic stem cells, blood cells, stem cells isolated from blood, placental stem cells, nucleated cells from placental perfusate, umbilical cord stem cells, blood-derived nucleated cells, bone marrow-derived mesenchymal stromal cells, bone marrow-derived mesenchymal stem cells, bone marrow-derived hematopoietic stem cells, crude bone marrow cells, adult stem cells, or fully-differentiated cells. 
     
     
         51 . The method of  claim 39 , wherein said population of cells is administered by bolus injection, intraperitoneally, intraarterially, intramuscularly, intradermally, or subcutaneously. 
     
     
         52 . The method of  claim 39 , wherein said population of cells is administered within an area of ischemia. 
     
     
         53 . The method of  claim 39 , wherein said population of cells is administered peripheral to an ischemia. 
     
     
         54 . The method of  claim 46 , wherein at least 70%, 80%, 90%, 95%, or 99% of the cells in said population are said amnion derived adherent cells. 
     
     
         55 . The method of  claim 47 , wherein at least 70%, 80%, 90%, 95%, or 99% of the cells in said population are said amnion derived adherent cells. 
     
     
         56 . The method of  claim 48 , wherein at least 70%, 80%, 90%, 95%, or 99% of the cells in said population are said amnion derived adherent cells.